Improvement of coronary-artery-plaque lipid-rich necrotic core seen with biologic therapy of psoriasis

Reuters Health - 15/09/2020 - Biologic therapy of psoriasis is associated with reductions in coronary-artery-plaque lipid-rich necrotic core (LRNC), according to a new study. "This is the first in-human evidence that this high-risk plaque feature can be stabilized and even reduced by treating a primary source of inflammation (the skin),” said Dr. Nehal N. Mehta of the National Heart, Lung, and Blood Institute, in Bethesda, Maryland. “Additionally, in the group that did not receive biologic therapy, the lipid-rich necrotic core tended to worsen, suggesting that unopposed inflammation is a dangerous thing for vascular health,” he told Reuters Health by email. LRNC is associated with increased cardiovascular events, and psoriasis is accompanied by systemic inflammation and a higher prevalence of coronary-artery disease. It remains unclear whether LRNC is affected by biologic therapy. Dr. Mehta and colleagues used data from 209 patients in the Psoriasis At...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 15 September, 202029 September, 2020